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Oliver P. March1,2, Thomas Lettner1, Alfred Klausegger1, Michael Ablinger1, Thomas Kocher1,
Stefan Hainzl1, Patricia Peking1,3, Nina Lackner1, Neil Rajan4, Josefina Pin˜o´n Hofbauer1,
Christina Guttmann-Gruber1, Anette Bygum5, Ulrich Koller1,6 and Julia Reichelt1,6Epidermolytic ichthyosis is a skin fragility disorder caused by dominant-negative mutations in KRT1 or KRT10.
No definitive restorative therapies exist that target these genetic faults. Gene editing can be used to efficiently
introduce frameshift mutations to inactivate mutant genes. This can be applied to counter the effect of
dominantly inherited diseases such as epidermolytic ichthyosis. In this study, we used transcription activator-
like effector nuclease technology, to disrupt disease-causing mutant KRT10 alleles in an ex vivo cellular
approach, with the intent of developing a therapy for patients with epidermolytic ichthyosis. A transcription
activator-like effector nuclease was designed to specifically target a region of KRT10, upstream of a premature
termination codon known to induce a genetic knockout. This proved highly efficient at gene disruption in a
patient-derived keratinocyte cell line. In addition, analysis for off-target effects indicated no promiscuous gene
editingemediated disruption. Reversion of the keratin intermediate filament fragility phenotype associated
with epidermolytic ichthyosis was observed by the immunofluorescence analysis of correctly gene-edited
single-cell clones. This was in concurrence with immunofluorescence and ultrastructure analysis of murine
xenograft models. The efficiency of this approach was subsequently confirmed in primary patient keratino-
cytes. Our data demonstrate the feasibility of an ex vivo gene-editing therapy for more than 95.6% of dominant
KRT10 mutations.
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tin intermediate filament (KIF) network of keratinocytes (KCs)
renders it unstable and sensitive to stress, resulting in the
collapse of keratin filaments into aggregates and formation of
blisters and erosions (Huber et al., 1994; Virtanen et al.,
2003). Increased basal proliferation and a grossly thickened
stratum corneum lead to the formation of hyperkeratotic
plaques. Current treatments rely on symptom management
and wound care, providing only temporary solutions
(Vahlquist et al., 2018).
Although rare, several recessive cases of EI have been
described (Arin et al., 2011; Mu¨ller et al., 2006; Terheyden
et al., 2009). The shared proximity of associated mutations
has led to the suggestion of a recessive EI “hotspot” located in
exon 6 of KRT10 (Terheyden et al., 2009). Heterozygotes for
these mutations display phenotypically normal epidermal
structure and differentiation, despite a 50% reduction in
KRT10 expression (Arin et al., 2011; Terheyden et al., 2009).
This advocates the targeting of KRT10 for a gene
disruptionebased EI therapy.
Recent advances in the development of programmable
sequence-specific nucleases have greatly improved our
ability to edit the genomes of eukaryotic cells (Guha et al.,
2017). Programmable nucleases enable targeted introduc-
tion of double-strand breaks at specific genomic locations
(March et al., 2018). Formation of double-strand breaks leads
to the recruitment of endogenous cellular repair machinery toestigative Dermatology. This is an open access
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1700repair the lesion, commonly via end-joining pathways
(Chang et al., 2017). These processes often result in insertion/
deletion (indel) mutations at the break point (Ceccaldi et al.,
2016). Indels often cause frameshift mutations that lead to
allelic disruption through activation of the nonsense-
mediated mRNA decay pathway (Nickless et al., 2017),
following the introduction of premature termination codons
(PTCs) into the reading frame (Supplementary Figure S1a
online). This can be exploited in a nonepatient-mutation-
specific manner, so that dominant alleles with mutations at
distinct locations might be knocked out via a single nuclease
in multiple patients (Aushev et al., 2017).
In this study, we demonstrate the development of an
efficient transcription activator-like effector nuclease
(TALEN)emediated ex vivo approach for therapeutic
disruption of mutant KRT10 alleles in KCs derived from
patients with EI (Supplementary Figure S1b). A key advan-
tage of TALENs over other programmable nucleases is their
ability to specifically target and efficiently cleave virtually
any sequence (March et al., 2018). EI phenotypic reversion
was demonstrated in corrected KCs and corrected
KCederived murine xenograft models. This was achieved
following specific TALEN targeting, efficient modification,
clonal expansion, screening and isolation of correctly
modified cells. The applicability of this approach was vali-
dated in primary patient cells. This represents proof-of-
principle for a viable TALEN-mediated therapy for more
than 95.6% of dominant-negative KRT10 mutations.RESULTS
Selection and design of a KRT10-specific TALEN
Of the currently reported recessive EI-associated mutations,
one results in an out-of-frame PTC (Figure 1a). This PTC,
located in exon 6 of KRT10 (c.1332), is induced via a
þ1/e2 frameshift (Figure 1b). Homozygotes for this muta-
tion demonstrate almost complete absence of KRT10
expression, without translation of a truncated protein
product (Terheyden et al., 2009). Concurrently, a second
PTC (c.1358) located 23 base pairs downstream remains
within the suggested recessive EI hotspot (Terheyden et al.,
2009) and is induced via a þ2/e1 frameshift. However,
KRT10 expression has not previously been described for
transcripts harboring this PTC.
We hypothesized that gene disruption upstream of these
two PTCs might induce nonsense-mediated decay of KRT10
transcripts in two frames, comprising an efficient method of
eliminating mutant keratin 10 (K10) from patient cells.
Following interrogation of the potential target sites within
this region, TALEN_6.21 was identified as best fitting neces-
sary design parameters (Cong et al., 2012; Meckler et al.,
2013; Reyon et al., 2012; Streubel et al., 2012) (Figure 1c).
TALEN_6.21 activity should disrupt a native MseI site located
centrally within the TALEN spacer, engendering simple
identification of modified KCs. Furthermore, in silico pre-
diction identified no highly homologous off-target sites for
this TALEN (Doyle et al., 2012). Although the binding site
falls within a KRT10 mutation hotspot, this is predicted to
lead to mismatches in only 4.5% of reported dominant-
negative EI cases (Szeverenyi et al., 2008).Journal of Investigative Dermatology (2019), Volume 139TALEN_6.21 activity was assessed in wild-type (NKc11)
and EI (EH31) KC cell lines, with the latter harboring a
sixebase pair deletion (c.481_486delTTGGAC) in exon 1 of
KRT10, via T7EI assay, without selection for transfected cells.
Confirmation of TALEN activity at the target site in both cell
lines demonstrated the potential of TALEN_6.21 to disrupt
KRT10 (Figure 1d). Strong gene disruption (56.8%) was sub-
sequently confirmed in TALEN_6.21-treated EH31 cells via
next-generation sequencing (NGS) of the target site, without
selection for transfected cells (Figure 1e).
Off-target analysis reveals no TALEN activity at predicted
sites
Although TALENs demonstrate strong specificity for target
sequences, off-target activity has been observed (Mussolino
et al., 2014).
Genomic loci, semihomologous to the TALEN_6.21 on-
target, were identified in silico (Figure 2a) (Doyle et al.,
2012). The TALEN_6.21 target site was partly selected
because of a lack of highly homologous sequences within the
genome. Therefore, all predicted off-targets display a mini-
mum of eight TALENeDNA mismatches. Indel formation was
analyzed at predicted off-target sites in TALEN_6.21-treated
EH31 cells via NGS (Figure 2b). Despite high on-target ac-
tivity, TALEN activity was not observed at off-target sites.
Screening for correctly modified keratinocyte clones
On-target indel formation was analyzed in TALEN_6.21-
treated EH31 cells via NGS. As expected, 66% of modifica-
tions resulted in frameshifts (Supplementary Figure S2a on-
line). Large deletions comprised the majority of modifications
(Supplementary Figure S2b and c). Biases in favor of several
distinct indels were also clearly observed (Figure 3a).
Modified single-cell clones were expanded from bulk-
treated samples. Tetraploidy of the EH31 cell line hindered
isolation of a clone harboring identical modifications on
mutant alleles (Supplementary Figure S3 online). Therefore,
two clones, AH2 and AE5, were isolated for further analysis
(Figure 3b).
AH2 carried distinct indels on each mutant allele
(Figure 3c). These induced PTCs at c.1332 and c.1358. To
ascertain that the latter resulted in efficient KRT10 knockout,
a control clone, AE5, was also isolated. AE5 carried an
identical indel on both wild-type alleles, inducing the PTC at
c.1332. Distinct indels on the mutant alleles induced PTCs at
c.1332 and c.1358. Unobserved off-target activity in clone
AH2 confirmed TALEN_6.21 specificity (Supplementary
Figure S4 online).
TALEN_6.21 on-target activity induces KRT10 knockout in
treated cells
K10 expression is normally restricted to differentiated
epidermis. Therefore, cultures of NKc11, EH31, AH2, and
AE5 were differentiated to drive K10 expression. To initially
confirm KRT10 knockout in differentiated AH2 and AE5
cultures, cDNA was subjected to allele- and noneallele-
specific PCR amplification of the EH31 mutation site
(Figure 4a). Absence of mutant KRT10 mRNA in AH2 and
complete absence of KRT10 mRNA in AE5 was indicated.
Sequence analysis of noneallele-specific products demon-
strated an absence of mutant transcripts in AH2. Sequence
Figure 1. Rational design of DSB site for efficient KRT10 knockout. (a) Schematic of KRT10 with the regions of all known dominant-negative mutations
(dark gray) and the only frameshift mutation known to cause transcript NMD (red) (b) Schematic of KRT10 exon 6 displaying the only out-of-frame PTC known to
induce transcript NMD (orange arrow), its associated frameshift mutation (red), an uncharacterized PTC induced via an alternative frameshift (green arrow) and
TALEN_6.21 binding sites (black lines). (c) TALEN_6.21 target site with spacer (blue), binding sites (bold), probable site of DSB induction (asterisk) and MseI
site used to identify modified alleles (purple). (d) TALEN_6.21 activity via T7EI assay. The presence of two correctly sized fragments (493 bp and 409 bp)
confirmed the on-target activity of TALEN_6.21 in both cell lines. Another TALEN that efficiently targets exon 6 downstream of both target PTCs was used as a
positive control in EH31. This would not be suitable for target PTC induction and KRT10 knockout (e) NGS analysis of TALEN_6.21 on-target activity
demonstrated strong gene disruption. bp, base pairs; DSB, double-strand break; NGS, next-generation sequencing; NMD, nonsense-mediated decay; PTC,
premature termination codon; TALEN, transcription activator-like effector nuclease.
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absence of TALEN-modified transcripts in AH2 (Figure 4b).
Truncated keratins and PTC read-through pose issues for
end-joiningebased gene therapies. These have a dominant-
negative disease effect in KIF (Fuchs et al., 1992; Porter
et al., 1996). Western blotting of lysates was performed, us-
ing C- and N-terminusespecific antibodies (Figure 4c).
Compared with the wild-type control, the EH31 cell line
showed stronger K10 expression. K10 expression was
reduced in AH2 to wild-type levels, suggesting partial K10
knockout. Complete absence of K10 was noted in AE5.
Neither of the a-K10 antibodies detected the protein in this
sample, indicating full K10 knockout. A single product was
detected in all K10-expressing samples, displaying an iden-
tical size to that found in a control skin sample. Thisindicated full degradation of mutant KRT10 mRNA and an
absence of PTC read-through or truncated K10 expression,
consistent with mRNA analysis.
Corrected EI single-cell clones demonstrate reversion of
disease phenotype
Mutant KRT10 knockout should restore intermediate filament
stability and revert the EI phenotype in AH2. Transient stress,
via heat shock assays, demonstrates the degree of fragility
within KIF (Chamcheu et al., 2009, 2011).
Differentiated monolayer cultures of NKc11, EH31, AH2,
and AE5 were analyzed by immunofluorescence analysis
following heat shock (Figure 5a). AH2 monolayers displayed
low levels of keratin aggregation, similar to wild-type sam-
ples. Absence of K10 in AE5 confirmed knockout. Mutantwww.jidonline.org 1701
Figure 2. TALEN_6.21 demonstrates high specificity in immortalized EI keratinocytes. (a) Summary of NGS analysis. TALEN_6.21 off-targets analyzed for
activity by NGS (red boxes in a and b). TALEN_6.21 on-target (blue box) and reverse orientation (gray box) also shown. Monomer binding conformation, spacer
(blue), central spacer nucleotide/s (underlined), mismatches (red letters), partial mismatches (green letters), and sequences shown. (b) TALEN_6.21 on-target and
off-target activity in bulk populations of TALEN-treated EH31 cells. On-target and off-target regions are listed, as are the number of NGS reads analyzed at
each site. Indel formation activity of TALEN_6.21 at on-target and off-target regions is represented as % indels relative to untreated control. The threshold
for activity at off-targets was set to 1%. EI, epidermolytic ichthyosis; indel, insertion/deletion; NGS, next-generation sequencing; TALEN, transcription activator-
like effector nuclease.
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1702EH31 cultures displayed widespread, large granular keratin
clumps in the majority of cells. In concurrence with protein
data, these cultures exhibited strong K10 expression and a
thickened KIF network. The KIF network of AH2 appeared
finer and more homogeneous. To assess cellular fragility
upon heat stress, the proportion of differentiated cells con-
taining keratin aggregates were evaluated in each culture.
Regardless of transient stress induction, keratin aggregation
observed in corrected samples did not exceed wild-type
levels (Supplementary Figure S5 online). This further indi-
cated restoration of KIF stability and alleviation of the EI
phenotype in AH2.
In vivo analysis was performed in murine xenograft models
(Figure 5). All samples demonstrated correctly localized
expression of K10 and K5 to suprabasal and basal layers
respectively, suggesting correct differentiation and stratifica-
tion (Supplementary Figure S6a online).
Analysis of xenografts via electron microscopy indicated
restoration of skin and KIF structure following inactivation ofJournal of Investigative Dermatology (2019), Volume 139the mutant KRT10 allele (Figure 5b). Keratin aggregation was
not apparent in wild-type and AH2 grafts, consistent with
alleviation of the KIF fragility phenotype. In contrast, wide-
spread keratin aggregation was observed throughout the
suprabasal layers of EH31 xenografts. Desmosome and ker-
atin filament structure also appeared phenotypically normal
and stable in corrected and wild-type samples. In EH31 xe-
nografts, keratin clumping was observed around desmo-
somes, as previously described (Fuchs et al., 1992; Porter
et al., 1996; Reichelt et al., 2001). This frequently appeared
disconnected from the KIF network of suprabasal cells.TALEN_6.21 editing is efficient and specific in primary EI
keratinocytes
The gene-editing therapy approach was validated in primary
KCs. Primary cells were obtained from a patient carrying a
heterozygous mutation (c.1333G>A) in exon 6 of KRT10
(Betlloch et al., 2009). This is located centrally within the
Figure 3. TALEN_6.21-modified single-cell clones were isolated from bulk populations featuring indel-specific bias. (a) Frequency of TALEN_6.21
modifications most commonly observed. Monomer binding sites (black), 13 bp spacer (blue), central spacer nucleotide (red), deletions (dashes), and insertion
sites (green). (b) Sanger sequencing chromatographs of edited EH31 clones and composition of individual alleles. Sequencing of clone AH2 displayed two
modifications on the mutant alleles only. Sequencing of clone AE5 displayed modifications on each allele. (c) Composition of modified alleles within clones
AH2 and AE5. bp, base pairs; indel, insertion/deletion; TALEN, transcription activator-like effector nuclease.
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Figure 4. KRT10 knockout in
TALEN_6.21-treated single-cell
clones. (a) cDNA PCR products
amplified from distinct differentiated
cultures in parallel. Noneallele-
specific KRT10 cDNA could not be
amplified from differentiated AE5
samples. KRT10 cDNA from wild-type
alleles could not be amplified from
AE5. Mutant KRT10 cDNA could not
be amplified from NKc11, AH2, or
AE5. (b) Sanger sequencing of KRT10
exons 1 and 6 from NKc11, EH31,
AH2, and AE5. (c) Western blot
analysis on whole differentiated cell
extracts via C- and N-terminal K10-
specific antibodies. Analysis revealed
a reduction of K10 for AH2 at protein
level compared with the untreated EI
cell line. AE5 displayed a total
absence of K10. No truncated
products were seen for either edited
clone. Wild-type K10 exhibits a size of
58.9 kDa. a-actinin was used as
loading control. EI, epidermolytic
ichthyosis; TALEN, transcription
activator-like effector nuclease.
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Figure 5. Reversion of EI phenotype in TALEN_6.21-treated single-cell clones. (a) Immunofluorescence staining of K10 (green) and desmoplakin (red) in
differentiated cultures following heat shock. Formation of K10 aggregates was demonstrated in diseased cells (EH31, arrows) but not in corrected clone AH2.
Absence of green staining confirmed knockout of K10 in clone AE5. Scale bars ¼ 100 mm and 10 mm (b) Murine modeling of modified clone skin xeno-
engraftment. H&E staining was performed on xenografts derived from NKc11, EH31, and AH2 cell lines. Scale bar¼ 20 mm. Electron microscopy of xenografts
confirmed the absence of keratin aggregation (arrows) and keratin clumping around desmosomes (asterisks) in wild-type and corrected grafts. Scale bar ¼
1,000 nm. D, dermis; E, epidermis; EI, epidermolytic ichthyosis; H&E, hematoxylin and eosin; SB, stratum basale; SS, stratum spinosum; TALEN, transcription
activator-like effector nuclease.
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single TALEN-target mismatch.
Primary EI cells were transfected with a green fluores-
cent protein vector (68.9% transfection efficiency) in
duplicate without selection (Supplementary Figure S7a
online). Similar efficiencies were assumed for TALEN_6.21.
NGS analysis of the TALEN_6.21 on-target site demon-
strated gene disruption efficiencies of 21.5%, with 25.5%
of modified alleles harboring the patient mutation
(Supplementary Figure S7b). Given that almost all frame-
shifts introduced at this target site would induce PTCs at
c.1332 and c.1358, resulting in KRT10 knockout, a ther-
apeutic efficiency of w3.7% could be expected within the
sample, not accounting for biallelic modification. NGS
analysis revealed no off-target activity above cutoff
threshold (Supplementary Figure S8 online).
Modified single-cell clones were expanded from a distinct
bulk-treated sample (Figure 6a). Single-cell expansion of
primary cells was 25.1% successful, with 611 cells seeded
and 153 clones identified. Of 32 clones analyzed for
TALEN_6.21 modification, 20 displayed indels at the on-
target site, eight demonstrated monoallelic modification,
and 12 displayed TALEN-induced indels on both alleles (data
not shown). All clones harbored distinct TALEN-induced
indels. Despite a reduced targeting capacity of TALEN_6.21
for mutant alleles, a clone (B8) harbored a monoallelic 1 base
pair deletion on the mutant allele (Figure 6b and c). This
resulted in the induction of a PTC at c.1358.
Taken together, this confirms the applicability of this
approach in a primary cell setting, despite the presence of a
mutation within the TALEN_6.21 target site.DISCUSSION
Introduction of a gene therapy agent before KC expansion and
engraftment is an effective strategy for the ex vivo treatment of
genetic disorders of the epidermis. In recessive diseases, this
can be efficiently achieved via retrovirus-mediated gene
replacement (Hirsch et al., 2017). However, integration site
and activity of the transgene cannot be controlled, presenting
limitations of retroviral delivery techniques (Boztug et al.,
2010; Hacein-Bey-Abina et al., 2008). These aspects and the
frequently dominant nature of EI engender the development of
gene editingebased therapies. Gene editing has been used to
permanently correct dominant (Kocher et al., 2017; Luan et al.,
2018) and recessive (Hainzl et al., 2017; Webber et al., 2016;
Wu et al., 2017) epidermolysis bullosaerelated mutations via
knockout and homologous recombination.
End-joining pathways, frequently co-opted for gene
knockout, comprise the most efficient repair pathways for
double-strand breaks (Danner et al., 2017). Gene knockout is
therefore the most efficient form of gene editing. TALEN_6.21
demonstrated high on-target activity in immortalized KCs
from a patient with EI (56.8%), compared with a recent gene-
editing approach targeting KRT5 in KCs derived from a pa-
tient with epidermolysis bullosa simplex (25%) (Aushev et al.,
2017). These high efficiencies were achieved without the use
of selection methods commonly employed in gene editing of
KCs (Hainzl et al., 2017; Kocher et al., 2017).
An issue with clustered regularly interspaced short
palindromic repeat (CRISPR)ebased approaches, employing
the commonly used Streptococcus pyogenes CRISPR-
associated protein 9, is that target sites are often limited
by the absence of an obligatory 50-NGG-30 protospacerwww.jidonline.org 1705
Figure 6. Primary patient single-cell expansion and TALEN_6.21 modification. (a) Microscopic appearance of representative TALEN_6.21-treated clones
grown for 14 days on fibroblast feeder cells. Red dashed line indicates clone extremity. Scale bars, upper panel ¼ 1,000 mm, lower panel 400 mm. (b) Sanger
sequencing chromatograms of edited primary patient clones. Six representative modified clone sequences are shown, each with distinct modifications following
analysis with CRISP-ID. (c) Composition of modified alleles within representative clones. Mutant nucleotide (A) within the right TALEN binding site is
highlighted in red and the wild-type (G) in green. TALEN, transcription activator-like effector nuclease.
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based targeting is a thymine 50 at the target site (Reyon
et al., 2012). TALENs are therefore able to target virtually
any sequence, to a greater degree than CRISPR/Cas systems
(March et al., 2018). This was crucial for the TALEN_6.21
approach, which aimed to surgically target a short region of
KRT10 directly 50 of a specific PTC. The successful complete
knockout of KRT10 demonstrated in this study indicates that
this strategy should be considered for other gene-editing
therapies for keratinopathies. In the absence of PTC char-
acterization, a homologous recombinationebased approach
might be preferred to avoid the potentially deleterious
consequences of truncated protein generation and provide
perfect sequence restoration. However, this would necessi-
tate development of patient-specific approaches.
Ex vivo application of this approach would comprise stem
cell isolation, TALEN-mediated gene editing, propagation of
patient KCs following correction of the genetic defect, and
surgical application to affected skin. This could be achieved
in a similar manner to the highly successful gene replace-
ment therapy that was recently used to treat almost the
entire epidermis of a boy with junctional epidermolysis
bullosa (Hirsch et al., 2017). Although demonstrated in a
limited fashion in this study, epidermal generation following
single-cell clonal expansion of gene-edited KCs is feasible
(Mencı´a et al., 2018). It is necessary to monitor off-target
activity, a key limitation of gene-editing therapies, where
off-target activity may prove detrimental (Cho et al., 2014;
Park et al., 2014). TALENs are known to tolerate single
mismatches (Mussolino et al., 2011). However, TALEN off-
target activity was not observed, as has been described in
a recent CRISPR-based KRT14 gene-editing study (Kocher
et al., 2017). In addition, highly allele-specific
TALEN_6.21-mediated gene disruption was demonstrated
in primary EI KCs that feature a single TALEN-target
mismatch.
To our knowledge, this study provides previously unre-
ported proof-of-principle that programmable nucleases can
be used to revert the cellular and histologic EI phenotype, in
an efficient and specific manner, through the inactivation of
mutant alleles. Our data demonstrate an efficiency, efficacy,
and specificity that could be feasibly applied to an ex vivo EI
gene-editing therapy.MATERIALS AND METHODS
Cell culture, transfection, clonal expansion, and
differentiation
Human immortalized EI KCs (EH31) from a male patient,
(Chamcheu et al., 2011), carrying a heterozygous mutation
(c.481_486delTTGGAC) in exon 1 of KRT10, and healthy KCs
(NKc11) (Chamcheu et al., 2009) from a male donor, were received
at low passage in August 2017 and cultured as previously described
(Chamcheu et al., 2011). Primary KCs were obtained from a skin
biopsy sample of a female patient with EI (IX) carrying a heterozy-
gous mutation (c.1333G>A) in KRT10 (Bygum et al., 2013). Written,
informed patient consent was obtained, and the project was
approved by the Danish Data Protection Agency Journal number 16/
31413. These cells were cultured in CNT-PR medium (CELLnTEC,
Bern, Switzerland) without supplements or antibiotics. KRT10 wassequenced for each sample to authenticate respective mutations.
Mycobacterial testing was performed with the MycoAlert PLUS
Mycoplasma Detection Kit (Lonza, Basel, Switzerland) as per the
manufacturer’s instructions.
Transfection of human KCs with TALEN plasmids was carried out
using Xfect (Takara Bio, Mountain View, CA), as previously
described (Aushev et al., 2017).
Immortalized and primary KC clonal expansion was performed
as previously described (Aushev et al., 2017), with minor modifi-
cations. TALEN-treated immortalized cells were isolated 10e14
days after transfection and passed through a 30-mm cell strainer
(Miltenyi Biotec, Bergisch Gladbach, Germany) before serial di-
lutions to obtain 0.4 cells per well in 96-well plates. TALEN-treated
primary cells were isolated 14 days after transfection and passed
through a 30-mm cell strainer before serial dilutions to obtain 0.8
cells per well in 96-well plates in coculture with 3T3-J2 mouse
fibroblast feeder cells (5e8  103 cells/cm2) growth-arrested with 4
mg/ml mitomycin C (Roche, Basel, Switzerland) for 2 hours at
37 C. Primary single-cell clones were cultured for 14 to 21 days
before analysis.
For differentiation, samples were cultured in CnT-PR medium
without supplements or antibiotics for 5e7 days. One day before
confluence, medium was exchanged with CnT-PR-D medium
(CELLnTEC). At confluency, 1.2 mM Ca2þ was added and main-
tained for 7 days.
Karyotyping of cell lines
Karyotype analysis was performed as previously described (Chou
et al., 2013), with 16 hours of colcemid treatment.
Flow cytometric analysis
Transfection efficiency was evaluated as previously described
(Hainzl et al., 2017; Kocher et al., 2017).
TALEN constructs
TALEN_6.21 was engineered as previously described (Aushev et al.,
2017; Mussolino et al., 2011).
Left monomer: NN_NI_NI_NG_NI_HD_HD_NI_NI_HD_NI_NI_
HD_NG_HD_HD_NG_NK.
Right monomer: NN_NI_NI_NG_NG_NG_HD_NI_NG_NG_
HD_NG_HD_HD_NI_NN_NG_HD.
T7EI assay
TALEN-mediated DNA mismatches upon repair of a double-strand
break at the target site were analyzed via T7EI assays (Guschin
et al., 2010) (New England Biolabs, Ipswich, MA). Genomic DNA
was isolated from cells using the ReliaPrep Blood gDNA Miniprep
System (Promega, Madison, WI) as per the manufacturer’s in-
structions 1 week after transfection. The TALEN_6.21 target site was
PCR-amplified using KRT10-specific forward (50-ACAGTCC-
CAACTGGCCTTGGT-30) and reverse (50-ACGGGGTGAGGTCA-
CATTCGG-30) primers. PCR products were isolated using the Illustra
GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Chi-
cago, IL).
Genotyping and single-cell cloning analysis
The TALEN target site was PCR-amplified and isolated from clones as
previously described (Hainzl et al., 2017) using KRT10-specific
forward (50-GCGTCACCATACTCAACTGAACAAG-30) and reverse
(50- CATGAGAAAGTGAGATTGCGGTTGC-30) primers. PCR prod-
ucts were digested with MseI FastDigest (Thermo Fisher Scientific,
Waltham, MA) to identify TALEN_6.21-modified clones.www.jidonline.org 1707
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(New England Biolabs). Wild-type, mutant, and combined alleles
were analyzed following PCR amplification via forward primers
binding directly to or upstream of EH31 mutation site. The primers
used were as follows: noneallele-specific forward (50-
ATGGTGGCCTTCTCTCTGGAAATGA-30), wild-typeespecific for-
ward (50-CGCCTGGCTTCCTACTTGGA-30), mutant-specific forward
(50-GCCTGGCTTCCtACAAAGTTC-30), and reverse (50-TGAGGT-
CACATTCGGTTATCTCT-30). Products were analyzed using CRISP-ID
software (Dehairs et al., 2016) following Sanger sequencing to
distinguish mixed sequencing products from edited samples.
Murine xenotransplantations
Generation and grafting of skin equivalents carrying EH31, NKc11,
and AH2 KCs were performed as previously described (Del Rio
et al., 2002). Five female animals were grafted per sample.
Engraftment was 60% (EH31), 80% (NKc11), and 80% (AH2) suc-
cessful. All grafts were harvested 8 weeks after transplantation.
Protein isolation and Western blot analysis
Cell pellets were homogenized with TRI Reagent/QIAzol (Sigma-
Aldrich, St. Louis, MO) and phase-separated via chloroform extrac-
tion. Protein was precipitated with isopropanol and pellets dissolved
in 8 M urea containing 7 complete protease inhibitor (Roche).
Protein concentration was determined via bicinchoninic acid pro-
tein assay (Thermo Fisher Scientific) as per the manufacturer’s
instructions.
Western blot analysis was performed as previously described
(Hainzl et al., 2017). Samples were blotted at 4 C overnight
(Supplementary Table S1 online). An actinin-specific antibody was
used as a loading control. Protein bands were visualized using the
Immobilon Western Chemiluminescent HRP Substrate (Merck,
Darmstadt, Germany) and the ChemiDoc XRS Imager (Bio-Rad,
Hercules, CA).
RNA analysis
RNAwas extracted with the innu-PREP RNA Mini Kit (Analytik Jena,
Jena, Germany) as per the manufacturer’s instructions. cDNA syn-
thesis was performed on RNA isolates using the GoScript Reverse
Transcriptase kit (Promega) as per the manufacturer’s instructions.
Allele-specific and noneallele-specific PCR was subsequently per-
formed on cDNA using forward primers mentioned previously and a
KRT10 cDNA-specific reverse (50-CTAGCAGGCTGCGGTAGGTTT-
30) primer, before Sanger sequencing.
Immunofluorescence analysis of thermally stressed
monolayers
Cells were seeded onto 35-mm glass bottom dishes (Cellvis,
Mountain View, CA) at overconfluence and differentiated before
thermal stress as previously described (Chamcheu et al., 2011).
Samples were fixed with precooled methanol for 10 minutes at e20
C and permeabilized in 1% BSA and 0.5% Triton X-100 (Sigma-
Aldrich) in phosphate buffered saline. For antibodies, see
Supplementary Table S2 online.
Analysis of xenografts
Punch biopsy samples were taken from harvested skin and frozen at
e20 C. Epidermal equivalents in OCT (SciGen, Singapore,
Singapore) were sectioned via a Leica cryostat (Leica Biosystems,
Wetzlar, Germany) at a thickness of 8 mm. For immunofluorescence
analysis, samples were fixed with precooled methanol for 10 mi-
nutes at e20 C and acetone for 20 seconds. Sections were subse-
quently permeabilized in 1% BSA and 0.5% Triton X-100 inJournal of Investigative Dermatology (2019), Volume 139phosphate buffered saline. For antibodies, see Supplementary
Table S2. Sections were analyzed using confocal laser scanning
microscopes Axio Observer Z1 attached to LSM700 and LSM710,
respectively (ZEISS, Oberkochen, Germany). For transmission elec-
tron microscopy, tissue was fixed, dehydrated, and embedded in
epoxy resin. Ultrathin sections (70 nm) were viewed on a CM100
TEM (Phillips, Amsterdam, Netherlands).
Next-generation sequencing (NGS)
We developed a TALEN-comprehensive AmpliSeq panel for NGS
analysis. This was designed and performed as previously described
(Kocher et al., 2017). The mean coverage of all nine genomic target
regions (on- and off-target) was 2,045 reads. For primers see
Supplementary Table S3 online.
Approval of animal studies
Animal studies were approved by the state review board (approval
no. BMWFW-66.019/0002-WF/V/3b/2016).
Statistical analysis
Data analysis was performed with Mann-Whitney and unpaired
Student t test. In addition, data analysis was performed with analysis
of variance with Dunn’s multiple comparison test and Bonferroni’s
multiple comparison test using Prism 5.03 (GraphPad Software, La
Jolla, CA).
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Supplementary
Figure S1. Therapeutic application of
the TALEN-mediated ex vivo gene
disruption approach. (a) Designer
nuclease-mediated gene disruption.
Following induction of a DSB- and EJ-
based DNA repair, deletions and
insertions may result in frameshifts in
the coding sequence. These may
introduce a PTC into the reading
frame. Transcripts containing PTCs are
subsequently targeted for decay via
the NMD pathway. (b) The TALEN-
mediated ex vivo approach. Following
isolation and expansion of EI patient-
derived KCs (1), TALENs are
transiently transfected (2). Transfected
cells are clonally expanded to
generate genetically identical
populations (3). These are screened for
KRT10 knockout-inducing
modifications and absent off-target
modification, with correctly modified
clones expanded (4). Epidermal sheets
are cultured ex vivo using correctly
modified clones (5) before re-
engraftment of corrected epidermis
onto the patient (6). DSB, double-
strand break; EI, epidermolytic
ichthyosis; EJ, end-joining; KC,
keratinocyte; NMD, nonsense-
mediated decay; PTC, premature
termination codon; TALEN,
transcription activator-like effector
nuclease.
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Supplementary Figure S2. Biases of
TALEN_6.21-mediated indel
formation at the KRT10 on-target.
Indel formation (n ¼ 994) at the
KRT10 on-target was assessed in bulk
TALEN_6.21etreated EH31 cells via
NGS analysis. (a) Modified alleles
displayed roughly equal incidence of
modifications for each frame, non-F/S
(34.00%), þ1/e2 (31.39%), þ2/e1
(34.61%). (b) The majority of
modifications resulted in overall
deletions (92.86%). Overall insertions
(6.84%) were more common than
overall substitution events (0.30) (c)
Summary of the observed frequencies
of each indel type (þ/D bp). Resultant
frameshift for each indel type is
indicated; non-frameshift (black), þ2/
e1 (dark gray), þ1/e2 (light gray). bp,
base pairs; F/S, frameshift; indel,
insertion/deletion; NGS, next-
generation sequencing; TALEN,
transcription activator-like effector
nuclease.
Supplementary
Figure S3. Aneuploidy of the EH31
cell line. The EH31 cell line displayed
aneuploidy across almost all
chromosomes. Many chromosomes
display trisomy, though several diploid
chromosomes are present. Four repeat
karyograms indicated Chromosome
17 tetraploidy in EH31 (red box).
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Supplementary Figure S4. TALEN_6.21 demonstrates high specificity in a corrected EI clone. Identical TALEN_6.21 off-targets were analyzed for activity by
NGS (red boxes) in clone AH2 samples as in bulk-treated samples. On-target and off-target regions are listed, as are the number of NGS reads analyzed at each
site. Indel formation activity of TALEN_6.21 at on-target and off-target regions are represented as % indels relative to untreated control. The threshold for activity
at off-targets was set to 1%. EI, epidermolytic ichthyosis; indel, insertion/deletion; NGS, next-generation sequencing; TALEN, transcription activator-like effector
nuclease.
Supplementary Figure S5. Reduced aggregate formation in corrected EI
cells with and without thermal stress. K10-positive cells containing keratin
aggregates were counted in NKc11, EH31, and AH2 differentiated
monolayers before (n ¼ 6) and after thermal stress (n ¼ 20). Aggregation was
observed in all samples as expected. Reduced aggregate formation was seen
in AH2, similar to levels shown in wild-type samples. The data are expressed
as aggregate-containing cells/K10-positive cells (mean  SEM). EI,
epidermolytic ichthyosis; SEM, standard error of the mean.
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Supplementary Figure S6. Correct
differentiation and stratification of
murine xenografts. (a)
Immunofluorescence co-staining of
N-terminal K10 (green) and K5 (red) in
murine xenografts derived from
NKc11, EH31, and AH2 cell lines.
DAPI (blue) indicates nuclei. All grafts
demonstrated well-defined basal
layers as expected. Scale bar ¼ 100
mm. (b) H&E staining of murine
xenograft. Human-murine boundary
indicated (red dashed line). Murine
skin was identified by the presence of
hair follicles (blue dashed lines) and a
generally thicker, cell-dense dermis.
Scale bar ¼ 100 mm. H&E,
hematoxylin and eosin.
Supplementary Figure S7. Successful
primary cell transfection. (a) Primary EI
KCs were transfected with pEGFP-C1 in
duplicate. These yielded approximate
efficiencies of 68.9% GFP-positive cells
(green) compared with untreated
controls. Transfection efficiency was
assessed 72 hours after transfection by
quantitative flow cytometry. SSC (y-axis)
was plotted against GFP fluorescence
(x-axis). Sample was gated for viable
cells. The total number of cells counted
for each sample was >8,000. (b) Indel
formation at the KRT10 on-target was
assessed in bulk-treated primary EI cells
via NGS analysis (n ¼ 1,064). (c) Allele-
specific indel formation at the KRT10
on-target was assessed in bulk-treated
primary EI cells via NGS analysis (n ¼
183). Reads featuring indels at the
mutation site were excluded (n ¼ 46).
EI, epidermolytic ichthyosis; GFP, green
fluorescent protein; indel, insertion/
deletion; KC; keratinocyte; NGS, next-
generation sequencing; SSC, side
scatter.
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Supplementary Table S1. Antibodies for Western
blotting
Antigen Antibody Species Reactivity Dilution
K10 (N-
terminal)
DE-K10 Mouse monoclonal Human/
mouse
1:5000
K10 (C-
terminal)
K10.1 Guinea pig
polyclonal
— 1:30000
Actinin a-actinin Mouse polyclonal Human 1:1000
a-mouse HRP Goat — 1:30000
a-guinea pig HRP Goat — 1:30000
Abbreviation: HRP, Horseradish Peroxidase.
Supplementary Figure S8. TALEN_6.21 demonstrates high specificity in primary EI keratinocytes. Identical TALEN_6.21 off-targets were analyzed for activity
by NGS (red boxes) in bulk-treated primary patient cell samples as bulk-treated immortalized samples. On-target and off-target regions are listed, as are the
number of NGS reads analyzed at each site. Indel formation activity of TALEN_6.21 at on-target and off-target regions are represented as % indels relative to
untreated control. The threshold for activity at off-targets was set to 1%. EI, epidermolytic ichthyosis; indel, insertion/deletion; NGS, next-generation sequencing;
TALEN, transcription activator-like effector nuclease.
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Supplementary Table S3. Primer Combinations for NGS
Localization Forward Primer Reverse Primer
17q21.2 (KRT10 exon 6) 50-ATCAAATAAGCGTCACCATACTCAACT-30 50-GGTTTAGATAAGCCTTGCTATCTGGA-30
4q12 (non-coding) 50-AATTGCTACTTCTTGTTTACCAGATCCA-30 50-GTCCCTCTAGAGAACCCTGACT-30
6q21 (non-coding) 50-ACTGGTTATTCTAGTTAGCAGTTCCTGT-50 50-CAACAACATCAACATCAAAGAAAAAGAC-30
6p22.1 (non-coding) 50-TTCTGACCAACCTCTACTAGCCA-30 50-ACCTCTGGTTGGATGACAATGG-30
4q31.3 (FHDC1 intron 6) 50-TGATTCCTTTTTAGTCCCTCCCTTT-30 50-ACGTCGCCACTAAACGCTTTTA-30
1p21 (non-coding) 50-ATGAGATTTCTGATTGAAGCAGATTCATTT-30 50-AAAGATGATCATGCTGGATGCTCA-30
2p25 (non-coding) 50-TCCCACCACTTACCTCTAGATATTAGC-30 50-TGACTCTGAGAATTCAGTAACGTTCAC-30
5q15 (non-coding) 50-GATACAACTCAGGAATAGTCAAATGGAAGA-30 50-CTGGGTTCCTGGCATAGAGTTC-30
1p36.3 (non-coding) 50-CATCCCTCTCCACATTGGGAAC-30 50-CTCTCATGCTCTGAGGTTGTCA-30
Abbreviation: NGS, next-generation sequencing.
Supplementary Table S2. Antibodies for Immunofluorescence Analysis
Antigen Antibody Species Reactivity Dilution
K1 AF109 Rabbit polyclonal Human/mouse 1:100
K5 AF138 Rabbit polyclonal Human/mouse 1:1000
K10 (N-terminal) DE-K10 Mouse monoclonal Human/mouse 1:100
K10 (C-terminal) K10.1 Guinea pig polyclonal — 1:5000
Desmoplakin Dp 495 Guinea pig polyclonal — 1:400
a-mouse Alexa 488 Goat — 1:400
a-mouse Alexa 594 Goat — 1:400
a-rabbit Alexa 488 Goat — 1:400
a-rabbit Alexa 594 Goat — 1:400
a-guinea pig Alexa 488 Goat — 1:400
a-guinea pig Alexa 594 Goat — 1:400
DAPI — — — 1:400
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